Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps.
Limitaciones de la determinación de calprotectina fecal en pacientes con colitis ulcerosa y pólipos inflamatorios.
Calprotectin
Calprotectina
Colitis ulcerosa
Enfermedad inflamatoria intestinal
Inflammatory bowel disease
Inflammatory polyps
Pólipos inflamatorios
Ulcerative colitis
Journal
Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
31
05
2019
revised:
10
07
2019
accepted:
22
08
2019
pubmed:
28
10
2019
medline:
5
1
2021
entrez:
26
10
2019
Statut:
ppublish
Résumé
Faecal calprotectin is a useful technique for detecting activity in patients with ulcerative colitis. However, there may be high levels due to factors other than the activity of ulcerative colitis. Our aim was to analyse possible false positive results of calprotectin for the activity of ulcerative colitis owing to the presence of inflammatory polyps. Retrospective, observational, descriptive study. Data was collected from patients monitored for 2 years in whom a colonoscopy had been requested within 3 months after detecting high calprotectin values (>150μg/g) and before modifying the treatment. We reviewed 39 patients and in 5 of them, with previous diagnosis of extensive ulcerative colitis, inflammatory polyps were detected. Three patients were on treatment with mesalazine, one with azathioprine and other with infliximab. All of them were asymptomatic and the endoscopy did not show macroscopic activity (endoscopic Mayo score=0) or histological activity. The median values of calprotectin were 422μg/g (IQR: 298-2,408) and they remained elevated in a second measurement. In 4 of the patients the inflammatory polyps were multiple and small in size. The other patient had a polyp measuring 4cm. In clinical practice we can find high faecal calprotectin levels not due to the presence of ulcerative colitis activity, but due to other lesions such as inflammatory polyps. This fact must be taken into account before carrying out relevant changes such as step-up therapy to immunosuppressive drugs or biological drugs in patients with confirmed high calprotectin levels.
Identifiants
pubmed: 31648810
pii: S0210-5705(19)30198-0
doi: 10.1016/j.gastrohep.2019.08.003
pii:
doi:
Substances chimiques
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Observational Study
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
73-78Informations de copyright
Copyright © 2019 Elsevier España, S.L.U. All rights reserved.